Assessing the Value of Newer Pharmacologic Agents in Non-ST Elevation Patients: A Decision Support System Application

Eric L. Eisenstein, Eric D. Peterson, James G. Jollis, Barbara E. Tardiff, Robert M. Califf, J. David Knight, Daniel B. Mark

Research output: Contribution to journalArticlepeer-review

Abstract

Newer pharmacologic agents have demonstrated significant clinical and economic benefit in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients. However, the higher costs of these agents may prohibit their use in lower-risk coronary artery disease (CAD) populations. We developed a decision support system (DSS) to determine the level of clinical effectiveness these newer agents must exhibit to be either cost-neutral or cost-effective in non-ST elevation patients. Our DSS evaluated six month cumulative costs, increased years of life saved (YOLS), and lifetime cost-effectiveness. We found that these therapies can cost as much as $1500 and be cost-neutral at six months if they reduce the composite endpoint of death, myocardial infarction (MI), or revascularization by 15%, and they may cost as much as $3000 and be cost-effective if they reduce this endpoint by 10%.

Original languageEnglish (US)
Pages (from-to)273-277
Number of pages5
JournalJournal of the American Medical Informatics Association
Volume4
Issue numberSUPPL.
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Health Informatics

Fingerprint

Dive into the research topics of 'Assessing the Value of Newer Pharmacologic Agents in Non-ST Elevation Patients: A Decision Support System Application'. Together they form a unique fingerprint.

Cite this